Jia Xiang
Directeur Financier/CFO chez HaploX Investment Holding Ltd.
Profil
Jia Xiang currently works at HaploX Investment Holding Ltd., as Chief Financial Officer & Board Secretary.
Mr. Xiang also formerly worked at Hydroelectric Corp., as M & A Director from 2015 to 2016.
Mr. Xiang received his graduate degree in 2020 from Shanghai Jiao Tong University.
Postes actifs de Jia Xiang
| Sociétés | Poste | Début |
|---|---|---|
HaploX Investment Holding Ltd.
 HaploX Investment Holding Ltd. Miscellaneous Commercial ServicesCommercial Services HaploX Investment Holding Ltd. engages in the provision of genetic testing solutions with a focus on using molecular diagnostics technologies. It offers genetic testing results that enable full cycle health management for cancer and other patients as well as health screening and risk assessment for individuals, genetic testing of pathogenic microbes, and other pathogens, to research and development genetic testing primarily for biopharmaceutical companies and research institutes. The company was founded by Ming Yan Xu, Yuan Wen, Shi Fu Chen, and Wen Fang on November 29, 2021 and is headquartered in Hong Kong. | Directeur Financier/CFO | - |
Anciens postes connus de Jia Xiang
| Sociétés | Poste | Fin |
|---|---|---|
| Hydroelectric Corp. | Corporate Officer/Principal | 01/01/2016 |
Formation de Jia Xiang
| Shanghai Jiao Tong University | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
| Hydroelectric Corp. | |
HaploX Investment Holding Ltd.
HaploX Investment Holding Ltd. Miscellaneous Commercial ServicesCommercial Services HaploX Investment Holding Ltd. engages in the provision of genetic testing solutions with a focus on using molecular diagnostics technologies. It offers genetic testing results that enable full cycle health management for cancer and other patients as well as health screening and risk assessment for individuals, genetic testing of pathogenic microbes, and other pathogens, to research and development genetic testing primarily for biopharmaceutical companies and research institutes. The company was founded by Ming Yan Xu, Yuan Wen, Shi Fu Chen, and Wen Fang on November 29, 2021 and is headquartered in Hong Kong. | Commercial Services |